Pyridorin in Diabetic Nephropathy

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 328 participants.

Also called NCT02156843

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 328 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02156843
  • EudraCT 2014-001641-24
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Australia, Bulgaria, France, Germany, Hong Kong SAR China, Hungary, Israel, Mauritius, Poland, Puerto Rico, Spain (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT02156843. Randomized; quadruple masking; primary purpose treatment. Start 2014-06 (registry gives no type); primary completion 2017-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Pyridorin in Diabetic Nephropathy
Acronym
PIONEER
Condition
Diabetic Nephropathy
Condition
Diabetic Kidney Disease
Intervention (Drug)
Pyridorin
Intervention (Drug)
Placebo
Lead sponsor
NephroGenex, Inc. (class: industry)
Collaborator
Collaborative Study Group (CSG) (class: research network)
Collaborator
Medpace, Inc. (class: industry)

Record details

Record id
cardio:ct-nct02156843
Content hash
ec33d10985f583d914b3d71e4f770c17dd4718ad6d7951720c1b2eb5db3cadf3